DOSSIER · 13F-HR · Q2 2026

Remedium Capital Partners, LLC

$452M in tracked AUM across 6 positions as of Q2 2026.

RC
CIK 0002104501 · last filed Jun 30, 2026
Total AUM
$452M
as of Q2 2026
Holdings
6
positions
Whale Score
69
69
tracked
Activity
no data
changes this Q
AI Analysis · Q2 2026

Remedium Capital Partners, LLC filed its latest 13F-HR for Q2 2026. See the latest holdings and position changes below.

Quarter at a glance — Q2 2026

Position-change comparison pending.

No quarter-over-quarter changes available.

Top 10 holdings

By portfolio weight as of Q2 2026.

#HoldingValueSharesWeight
01
ORKA
Oruka Therapeutics Inc
$149M1.6M33.0%
02
SYRE
Spyre Therapeutics Inc
$130M1.5M28.8%
03
APGE
Apogee Therapeutics Inc
$78M587K17.2%
04
GLTO
Damora Therapeutics Inc
$53M2.0M11.8%
05
JBIO
Jade Biosciences Inc
$35M1.6M7.8%
06
G2545C104
Crescent Biopharma Inc
$7M361K1.4%

Filing history

2026Q2Jun 30
$452M 60.6%
6 positionsView →
2026Q1Mar 31
$281M 65.2%
6 positionsView →
2025Q4Dec 31
$170M
6 positionsView →